Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has submitted to BSE and NSE a copy of the newspaper advertisement publishing its unaudited consolidated financial results for the quarter ended June 30, 2025, which appeared in Financial Express on August 13, 2025. For Q1 FY26, total income from operations stood at Rs 6,532.7 crore, up about 5.2% from Rs 6,207.5 crore in Q1 FY25. Net profit for the quarter came in at Rs 1,466.8 crore versus Rs 1,419.9 crore in the year-ago quarter, a growth of roughly 3.3%. Basic and diluted EPS for the quarter was Rs 14.58, compared to Rs 14.11 in Q1 FY25. The results were also made available on the company's website, BSE, and NSE portals.
The Q1 numbers show modest, low-single-digit growth in both revenue and profit, indicating a stable but not breakout quarter. For shareholders, the EPS uptick is mildly positive, but the lack of strong acceleration may limit any meaningful upside reaction in the stock on the back of this filing alone.